This database contains 162 studies, archived under the term: "Before and After Study"
Click here to filter this large number of results.
Translating the REACH caregiver intervention for use by area agency on aging personnel: The REACH OUT Program
Burgio, Louis D.,
Collins, Irene B.,
Schmid, Bettina,
Wharton, Tracy,
McCallum, Debra,
DeCoster, Jamie
Purpose: The aim of this study was to translate the evidence-based Resources for Enhancing Alzheimer’s Caregiver Health (REACH) II intervention for use in 4 Area Agencies on Aging (AAAs). A secondary aim was to examine possible moderators of treatment outcome. Design and Methods: We used a quasi-experimental pre-post treatment design with no control group. A […]
Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease
Uenaka, Kazunori,
Nakano, Masako,
Willis, Brian A.,
Friedrich, Stuart,
Ferguson-Sells, Lisa,
Dean, Robert A.,
Ieiri, Ichiro,
Siemers, Eric R.
Objectives: Solanezumab is a humanized anti-amyloid β monoclonal antibody being developed as a passive immunization treatment to slow the progression of Alzheimer disease (AD). Pharmacokinetics (PK), pharmacodynamics, safety, and tolerability after a single dose of solanezumab were compared between Japanese and white patients with AD.; Methods: Japanese and white patients with mild to moderate AD […]
Increased cerebral metabolism after 1 year of deep brain stimulation in Alzheimer disease
Smith, Gwenn S.,
Laxton, Adrian W.,
Tang-Wai, David F.,
McAndrews, Mary Pat,
Diaconescu, Andreea Oliviana,
Workman, Clifford I.,
Lozano, Andres M.
Background: The importance of developing unique, neural circuitry-based treatments for the cognitive and neuropsychiatric symptoms of Alzheimer disease (AD) was the impetus for a phase I study of deep brain stimulation (DBS) in patients with AD that targeted the fornix.; Objective: To test the hypotheses that DBS would increase cerebral glucose metabolism in cortical and […]
Evaluation of the regional cerebral blood flow changes during long-term donepezil therapy in patients with Alzheimer’s disease using 3DSRT
Kimura, Noriyuki,
Kumamoto, Toshihide,
Masuda, Teruaki,
Hanaoka, Takuya,
Okazaki, Toshio,
Arakawa, Ryuki
Background: We attempt to evaluate objectively the regional cerebral blood flow (rCBF) changes during long-term donepezil therapy and the relationship between the clinical response and rCBF change in patients with Alzheimer’s disease (AD).; Patients and Methods: Thirty-one patients with mild-to-moderate AD (11 men, 20 female; mean age, 76.2 ± 6.7 years) were treated with donepezil […]
Greater responsiveness to donepezil in Alzheimer patients with higher levels of acetylcholinesterase based on attention task scores and a donepezil PET study
Kasuya, Masashi,
Meguro, Kenichi,
Okamura, Nobuyuki,
Funaki, Yoshihito,
Ishikawa, Hiroyasu,
Tanaka, Naofumi,
Iwata, Ren,
Yanai, Kazuhiko
The aim of the study was to predict donepezil responders among patients with Alzheimer disease (AD) based on cognitive tests and positron emission tomography. The Mini-Mental State Examination, Digit Symbol subtest (DigSm) of Wechsler Adult Intelligence Scale Revised, and Trail-Making Test A were administered for 80 patients with AD to assess global function, attention, and […]
Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia
Herrmann, Nathan,
Black, Sandra E.,
Chow, Tiffany,
Cappell, Jaclyn,
Tang-Wai, David F.,
Lanctôt, Krista L.
Objectives: The purposes of this study were first, to evaluate the effectiveness of citalopram in treating behavioral disturbances in frontotemporal dementia (FTD) subjects and second, to determine whether an association exists between serotonergic function, as determined by a neuroendocrine challenge, and treatment response.; Design: Single-dose citalopram (30 mg per os) challenge followed by a 6-week […]
Developing an educational intervention on dementia diagnosis and management in primary care for the EVIDEM-ED trial
Iliffe, Steve,
Koch, Tamar,
Jain, Priya,
Lefford, Frances,
Wong, Geoffrey,
Warner, Alex,
Wilcock, Jane
Background: Dementia syndromes are under-diagnosed and under-treated in primary care. Earlier recognition of and response to dementia syndrome is likely to enhance the quality of life of people with dementia, but general practitioners consistently report limited skills and confidence in diagnosis and management of this condition. Changing clinical practice is difficult, and the challenge for […]
Is high oral dose L-arginine intake effective in leukoaraiosis? Preliminary data, study protocol and expert’s opinion
Calabro, Rocco Salvatore,
Gervasi, Giuseppe,
Baglieri, Annalisa,
Furnari, Anna,
Marino, Silvia,
Bramanti, Placido
Background: Leukoraraiosis is worldwide considered as a part of the normal aging process, although it is strongly associated with dementia and other disabilities. The pathogenesis of leukoaraiosis still has not been thoroughly acknowledged, even though chronic ischemia with consequent arteriolosclerosis probably due to endothelial dysfunction has been suggested. Treatment focuses on prevention of lesion formation […]
Improvement in delusions and hallucinations in patients with dementia with Lewy bodies upon administration of yokukansan, a traditional Japanese medicine
Iwasaki, Koh,
Kosaka, Kenji,
Mori, Hideo,
Okitsu, Reina,
Furukawa, Katsutoshi,
Manabe, Yuta,
Yoshita, Mitsuhiro,
Kanamori, Aya,
Ito, Nobuo,
Wada, Kenji,
Kitayama, Michio,
Horiguchi, Jun,
Yamaguchi, Shuhei,
Takayama, Shin,
Fukuhara, Ryuji,
Ouma, Shinji,
Nakano, Seigo,
Hashimoto, Mamoru,
Kinoshita, Toru
Background: This multicentre open-label trial examined the efficacy and safety of the traditional Japanese medicine, or Kampo medicine, yokukansan (YKS), for behavioural and psychological symptoms of dementia (BPSD) in patients with dementia with Lewy bodies.; Methods: Sixty-three dementia with Lewy bodies patients with probable BPSD (M:W, 30:33; mean age, 78.2±5.8 years) were enrolled and treated […]